Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 1
2016 1
2017 3
2018 10
2019 20
2020 25
2021 24
2022 18
2023 18
2024 14
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 38159972

112 results

Results by year

Filters applied: . Clear all
Page 1
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H. Uryu K, et al. Jpn J Clin Oncol. 2024 Mar 9;54(3):319-328. doi: 10.1093/jjco/hyad162. Jpn J Clin Oncol. 2024. PMID: 37997468
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O, Stratmann JA, Wiesweg M, Eberhardt W, Metzenmacher M, Schmid KW, Herold T, Schildhaus HU, Darwiche K, Aigner C, Stuschke M, Laue K, Zaun G, Kasper S, Hense J, Sebastian M, Schuler M, Pogorzelski M. Kraskowski O, et al. J Cancer Res Clin Oncol. 2023 Sep;149(11):9243-9252. doi: 10.1007/s00432-023-04839-3. Epub 2023 May 18. J Cancer Res Clin Oncol. 2023. PMID: 37198447 Free PMC article.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Soria JC, et al. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Free article. Clinical Trial.
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G. Dal Maso A, et al. Future Oncol. 2021 Jul;17(19):2513-2527. doi: 10.2217/fon-2021-0356. Epub 2021 May 14. Future Oncol. 2021. PMID: 33988036 Free article.
112 results